Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical PracticeTerminated
NCT07036718N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
Russia
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab EmiratesNot Yet Recruiting
NCT07465666N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Hypertension
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With SecukinumabNot Yet Recruiting
NCT07454889N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in KoreaCompleted
NCT05621733N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Graft-versus-Host Disease
South Korea
Pluvicto Real-world Investigation in Survival in Metastatic CRPCNot Yet Recruiting
NCT07697989N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis
Asciminib in HER2+ Breast Cancer Brain MetastasesRecruiting
NCT07136428Phase 1, Phase 2Updated Jul 22, 2026
Sponsor: Duke University
HER2+ Metastatic Breast Cancer
United States
A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric ParticipantsRecruiting
NCT07716410N/AUpdated Jul 21, 2026
Sponsor: Novartis Pharmaceuticals
Cryptosporidiosis
Kenya, Malaysia, Zambia
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)Recruiting
NCT06649110Phase 1, Phase 2Updated Jul 21, 2026
Sponsor: Novartis Pharmaceuticals
Healthy Volunteers, Pulmonary Arterial Hypertension
United States, Argentina, Australia, Belgium, Brazil +13 more
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLDRecruiting
NCT07683065N/AUpdated Jul 21, 2026
Sponsor: Novartis Pharmaceuticals
Plaque Psoriasis · Metabolic Dysfunction-Associated Steatotic Liver Disease
Spain
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic DermatitisRecruiting
NCT07604324Phase 1Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Dermatitis, Atopic
Japan
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompleted
NCT05834738Phase 2Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
IgA Nephropathy · Immunoglobulin A Nephropathy
United States, Australia, Brazil, Malaysia, South Korea +1 more
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian PopulationRecruiting
NCT07543419N/AUpdated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
Italy
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated MalariaNot Yet Recruiting
NCT07713602Phase 4Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Malaria
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy AdultsRecruiting
NCT07249463Phase 2Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Cryptosporidiosis
United States
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.Active Not Recruiting
NCT05921994N/AUpdated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
Germany
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upActive Not Recruiting
NCT05677451Phase 3Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
United States, Argentina, Canada, Chile, China +12 more
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseActive Not Recruiting
NCT05030428Phase 3Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
United States, Argentina, Australia, Austria, Belgium +45 more
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseaseRecruiting
NCT06546670Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
United States, Turkey (Türkiye)
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved RemissionActive Not Recruiting
NCT05622708Phase 4Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Non-radiographic Axial Spondyloarthritis
Belgium, Brazil, Colombia, Czechia, France +13 more
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) TherapyRecruiting
NCT07091019N/AUpdated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
United States
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.Recruiting
NCT06858319Phase 3Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Kidney Diseases · Kidney Diseases, Chronic · Urological Diseases · Glomerulonephritis
United States, Argentina, Australia, Canada, Malaysia +1 more
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)Recruiting
NCT07387926Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Israel
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruiting
NCT04104776Phase 1, Phase 2Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell · Mesothelioma, Malignant
United States, France, Italy, Poland, South Korea +2 more
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Recruiting
NCT07357727Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)
United States, Argentina, Australia, China, India +3 more
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCActive Not Recruiting
NCT05849298Phase 2Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasm
United States, Brazil, Canada, Czechia, France +6 more

Previous page Next page